- 6 - Foster *et al.* Appl. No.: (Natl. Phase of PCT/GB00/01247)

Remarks

By the foregoing amendments, claims 1-29 have been cancelled without prejudice or disclaimer. New claims 30-47 are sought to be entered. Support for the foregoing amendments to the claims may be found throughout the specification and in the claims as originally filed. Accordingly, the present amendments do not add new matter, and their entry is respectfully requested. Upon entry of the foregoing amendments, claims 30-47 are pending in the application, with claims 30 and 45 being the independent claims.

It is believed that the present application is in condition for immediate examination. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond Attorney for Applicants Registration No. 32,893

Sbutu. Somon

Date: Sept. 26,2001

1100 New York Avenue, N.W. Suite 600 Washington, D.C. 20005-3934 (202) 371-2600

P: USERS MTRAN 1581 087000 prelimamend.wpd SKGF Rev. 3:16:01

Version with markings to show changes made

In the Specification:

In the specification at page 1, before line 1, please insert the following paragraph:

The present application is a 371 of PCT/GB00/01247 filed on March 31, 2000, and

published in English on October 5, 2000, the disclosure of which is incorporated herein by

reference in its entirety.

In the Abstract:

Please insert following abstract on page 44 after the claims:

The present invention relates to the treatment of pain and to compounds that

modulate C-fibre activity. In particular, the present invention relates to the use of a lectin

in the manufacture of a medicament for modulation of C-fibre neuron activity, and to lectin

conjugates. The lectin conjugates comprise a lectin coupled to a peptide or protein, wherein

the peptide or protein is substantially free of Clostridial neurotoxin enzyme activity. The

present invention also concerns methods for manufacturing conjugates. The compounds and

compositions described have particular application in the treatment of diseases of which

C-fibre activity is a component. Such diseases include pain, inflamation, psoriasis and other

C-fibre related conditions.

In the Claims:

Claims 1-29 have been cancelled.

New claims 30-47 are sought to be entered.